Sponsors often describe their challenges in clinical trials using familiar terms: oversight, timelines, compliance, and coordination. Beneath all these concerns sits a quieter but more persistent issue: portfolio visibility.
Most sponsor organizations do not struggle because they lack data. They struggle because the same information exists in multiple places, in slightly different forms, at different points in time. When leadership asks a simple question, “Where do things stand?” the answer frequently requires reconciliation rather than insight.
This is the problem sponsors mean when they talk about the need for a “single source of truth.” Yet in practice, achieving one remains elusive and thus, common pleas from clinical trial sponsors.
What sponsors usually have instead of a single source of truth
In most clinical programs, critical information is distributed across multiple systems and processes:
- Clinical data lives within the EDC
- Operational milestones and enrollment status are tracked in a CTMS or spreadsheets
- Regulatory documentation and completeness status reside in the eTMF
- Additional context is maintained through emails, slide decks, trackers, and status reports
Each system may function correctly on its own. The challenge arises when sponsors attempt to view the trial as a whole, or across multiple trials, without a reliable way to see how these elements align.
As a result, portfolio‑level discussions often revolve around questions such as:
- Which figure is current?
- Why does enrollment status differ between reports?
- Has a milestone been completed, or just planned?
- Is documentation lagging because the work hasn’t happened, or because it hasn’t been filed yet?
These questions are not signs of poor execution. They are symptoms of fragmented information.
When portfolio meetings become reconciliation meetings
Portfolio reviews are intended to support decision‑making. Instead, they frequently begin with reconciliation.
Time is spent comparing reports, validating dates, and aligning definitions. By the time a shared understanding emerges (if it does) much of the meeting has been consumed by aligning facts rather than discussing implications.
This dynamic creates several downstream effects:
- Decisions are delayed because confidence in the data is incomplete
- Risks are identified later than they could be
- Teams rely more heavily on manual explanations and follow‑up
- Leadership develops a sense that visibility is always slightly behind reality
Over time, the organization adapts to this state. Status updates become more frequent. Spreadsheets multiply. Additional layers of reporting are added in an attempt to compensate.
Yet none of these measures resolves the underlying issue: the absence of a shared operational reference point.
Why reconciliation becomes unavoidable in multi‑system environments
Reconciliation is not usually caused by a lack of discipline. It results from how systems are designed to operate independently.
When key trial events such as site activation, subject enrollment, monitoring completion, or document finalization are recorded separately across systems, differences in timing and context are inevitable. A milestone may be completed operationally before documentation is finalized. Data may be entered but not yet reviewed. A site may be active in one system and pending in another.
Each system tells a partial version of the story. Reconciliation becomes the means by which these versions are stitched together.
While this approach can function in a single study with limited complexity, it becomes increasingly fragile as portfolios grow.
The compounding effect at the portfolio level
Sponsors managing more than one active study experience a compounding effect.
Each additional program introduces:
- Another set of timelines
- Another combination of vendors and partners
- Another flow of documents and data
- Another reporting cadence
Without a consistent operational backbone, differences in structure and timing accumulate. Portfolio‑level oversight becomes less about seeing trends and more about verifying accuracy on a study‑by‑study basis.
At this stage, the organization may still describe its challenge using familiar terms such as visibility gaps, delayed insight, or limited oversight, but the core issue remains unchanged. There is no shared, current representation of what is happening across trials.
Why “single source of truth” is often misunderstood
The phrase “single source of truth” is frequently interpreted as a data‑warehousing or reporting problem. Sponsors may attempt to address it by consolidating reports or building dashboards fed by multiple sources.
While aggregated reporting can help, it often introduces its own limitations. Reports typically reflect snapshots in time rather than living workflows. They rely on downstream reconciliation rather than preventing fragmentation at the source.
A true single source of truth is not simply a consolidated view. It is a shared operational context, one in which key events, data, and documentation are aligned as work progresses.
This distinction matters because it determines whether visibility is always retrospective or genuinely current.
Why delayed visibility matters even when trials appear “on track”
Sponsors sometimes accept reconciliation as an inconvenience rather than a risk, particularly when trials appear to be progressing acceptably.
However, delayed visibility can have subtle consequences:
- Emerging risks are identified later, narrowing response options
- Timeline forecasts become less reliable
- Resource allocation decisions are made with incomplete context
- Leadership confidence erodes as updates require qualification
None of these issues typically manifest as immediate failures. Instead, they contribute to a sense that outcomes are harder to predict than they should be.
For sponsors managing investor expectations or transition points between development phases, predictability matters as much as progress.
Control versus visibility: what sponsors are really seeking
When sponsors speak about portfolio visibility, they are rarely asking for more reports. They are seeking control. Not in the sense of micromanagement, but in the ability to understand what is happening without translation.
Control, in this context, means:
- Knowing whether work is pending, completed, or delayed
- Understanding how documentation status reflects operational activity
- Detecting misalignment between plan and execution early
- Being able to trust that what is seen reflects current reality
A single source of truth supports control by reducing the need for interpretation.
The limitations of manual alignment
In many organizations, experienced teams compensate for system fragmentation through institutional knowledge. They know which reports to trust, how to interpret lag, and when discrepancies are meaningful versus benign.
While this expertise is valuable, it does not scale indefinitely. As teams change, portfolios expand, or external partners vary, reliance on manual interpretation increases risk.
Moreover, manual alignment concentrates critical knowledge in a small number of individuals. When those individuals are unavailable, visibility degrades quickly.
Moving toward shared operational context
Sponsors that make progress toward a single source of truth typically do so by focusing less on reports and more on alignment.
Alignment means that:
- Operational events trigger corresponding data and documentation workflows
- Milestones are reflected consistently across systems
- Status reflects both completion and completeness
- Oversight does not depend on post‑hoc reconciliation
This approach does not eliminate complexity. It reduces the effort required to understand it.
Why this issue persists across the industry
The persistence of portfolio visibility challenges is not the result of neglect. It is a structural consequence of how clinical trial systems evolved separately to address specific needs.
As regulatory expectations, therapeutic complexity, and portfolio breadth increase, the gaps between systems become more visible.
Sponsors are not alone in facing this challenge. CROs, sites, and regulators all experience its effects in different ways. However, sponsors bear the accountability for understanding and responding to what is happening across their programs.
Reframing the question sponsors ask
Rather than asking, “Why don’t we have better reports?”, many sponsor organizations benefit from reframing the question:
- Where does reconciliation occur today?
- Which decisions require clarification before they can be made?
- At what points does visibility lag reality?
These questions point not to reporting deficiencies, but to workflow alignment.
Your source of truth: seeing the portfolio as it is, not as it was
A true single source of truth allows sponsors to see their portfolio as it exists now, not as it appeared in the last reporting cycle.
This difference is subtle until it becomes critical. When timelines tighten, changes occur mid‑study, or risks emerge unexpectedly, real‑time alignment becomes the difference between proactive response and reactive correction.
Portfolio visibility is not just a reporting problem. It depends on whether clinical data, operational milestones, and regulatory documentation are connected as work happens. That is why an integrated EDC, CTMS, and eTMF model gives sponsors a clearer view of what is actually happening across their studies.
View our latest press release.
Related Articles: